Medical College of Wisconsin: Leukemia, Myeloid trials

The registry lists 13 Leukemia, Myeloid studies with Medical College of Wisconsin as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 4Phase 3 5Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid LeukemiaTerminatedNCT03988205Phase 4Results posted
• TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)CompletedNCT03959241Phase 3Results posted
• The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)CompletedNCT02269267Phase 2Results posted
• Double Cord Versus Haploidentical (BMT CTN 1101)CompletedNCT01597778Phase 3Results posted
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)TerminatedNCT01339910Phase 3Results posted
• Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord UnitTerminatedNCT01050946Phase 2Results posted
• Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)CompletedNCT00864227Phase 2Results posted
• Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)CompletedNCT00849147Phase 2Results posted
• Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)CompletedNCT00412360Phase 3Results posted
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)CompletedNCT00406393Phase 3Results posted
• Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaWithdrawnNCT06007911Phase 1
• Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaTerminatedNCT04172844Phase 1
• Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441048Phase 1